C50
Conditions
Interventions
Group 1: Women with estrogen receptor positive breast cancer who have already donated samples and data to PATH Biobank during their primary surgery will be invited to the study for longitudinal, prosp
Sponsors
Stiftung PATH Biobank
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: sample donation for the PATH Biobank at timepoint of primary surgery, estrogen receptor positive breast cancer, antihormonal therapy reported in follow-up and within the last, fifth year of therapy
Exclusion criteria
Exclusion criteria: other therapy for BC (breast cancer) than ET ongoing, inflammatory cancers, pregnancy, any medical condition (e.g. substance abuse) that may, in the clinical judgement of the investigator, independently influence the subject’s outcome during this study, participation in another interventional clinical trial within the last four weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of MESI (metabolic and signal network) marker panel alterations in serum and urine in the presence and absence of ET (Endocrine Therapy) | — |
Secondary
| Measure | Time frame |
|---|---|
| Analysis of serum/urine from patients before and after termination of ET and comparison to clinical follow-up may allow identification of MESI marker alterations predictive of recurrence after termination of ET (Endocrine Therapy) | — |
Countries
Germany
Contacts
Public ContactTobias Anzeneder
Stiftung PATH Biobank
Outcome results
None listed